Alnylam Pharmaceuticals (ALNY) FCF Margin Growth (5y) (2014 - 2026)

Alnylam Pharmaceuticals (ALNY) FCF Margin Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 14,099.00
Dec 31, 2025 6,483.00
Sep 30, 2025 12,465.00
Jun 30, 2025 17,698.00
Mar 31, 2025 23,235.00
Dec 31, 2024 42,504.00
Sep 30, 2024 19,840.00
Jun 30, 2024 -50,978.00
Mar 31, 2024 58,840.00
Dec 31, 2023 45,164.00
Sep 30, 2023 1.07 Mn
Jun 30, 2023 36,282.00
Mar 31, 2023 70,200.00
Dec 31, 2022 1,408.00
Sep 30, 2022 69,244.00
Jun 30, 2022 58,284.00
Mar 31, 2022 63,119.00
Dec 31, 2021 52,045.00
Sep 30, 2021 61,670.00
Jun 30, 2021 91,723.00